Condition: Cholangiocarcinoma · Sponsor: Servier Affaires Médicales
A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA). All patients who meet inclusion criteria will be enrolled to receive ivosidenib tablets orally once daily for 28 day cycles, continuing as long as clinical benefit and consent for participation is maintained. There will be a minimum of 6 study visits from screening until the final follow-up, if one cycle of treatment is completed and consent is maintained through 18 months of follow-up. Each additional cycle completed will add one study visit, on the first day of each cycle.
This description comes directly from the study's public registry record.
Institut de Recherches Internationales Servier, Clinical Studies Department · +33 1 55 72 60 00 · scientificinformation@servier.com
Always discuss trial participation with your own doctor first.
| Erebouni MC | Yerevan, Armenia | Completed |
| National Center of Oncology of Ra M | Yerevan, Armenia | Completed |
| Royal brisbane & Women's Hospital | Brisbane, Australia | Completed |
| St Vincent's Hospital | Fitzroy, Australia | Completed |
| St John of God Hospital - Bendat Family Comprehensive Cancer Centre (BFCCC) | Subiaco, Australia | Completed |
| Kinghorn Cancer Centre | Sydney, Australia | Completed |
| The Queen Elizabeth Hospital | Woodville, Australia | Completed |
| Medizinische Universitaet Graz | Graz, Austria | Completed |
| Ordensklinikum Linz GmbH | Linz, Austria | Completed |
| Universitaetsklinik fuer Innere Medizin III, mit Hämatologie, internistischer Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum | Salzburg, Austria | Completed |
| Medizinische Universitaet Wien Universitaetsklinik fuer Innere Medizin I | Vienna, Austria | Completed |
| Universite Libre de Bruxelles ULB - | Brussels, Belgium | Completed |
+ 72 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05876754